Failed Resolution: Why mRNA Experiments Must Halt

Executive Summary

The vaccine that was supposed to save billions of lives wasn't the same one they used on the public. The vaccine tested in trials (Process 1) was replaced with a different manufacturing process (Process 2) that contains bacterial DNA with active viral promoters—contamination that internal regulatory documents show alarmed scientists while public assurances dismissed it.

Why this matters: This DNA isn't inert. The m⁶A methylation pattern confirms it came from E. coli. The SV40 promoter is unmethylated and biologically active. Together, they can trigger chronic immune activation, may interfere with antibody production through somatic hypermutation disruption, and carry integration risks that weren't adequately studied.

The evidence: 9+ independent labs across four continents have confirmed contamination levels up to 627-fold above regulatory limits. The batch variance (815-fold) reveals systemic manufacturing control failure.

What we don't know: The long-term clinical consequences of chronic DNA exposure via lipid nanoparticles. Population-level data won't be visible for 5-10 years if solid tumors are the endpoint.

Mechanistic context: Rauf et al. (2026, Clinical Immunology) show that Long COVID involves failed innate immune resolution via efferocytosis impairment and AXL/TAM receptor hijack by persistent spike protein. If this mechanism is correct, mRNA vaccines which produce persistent spike protein may exacerbate rather than prevent the problem.

Between clinical trials and global deployment, three things changed without adequate safety assessment:

Manufacturing Process Switch: Trial vaccine (Process 1) to deployed vaccine (Process 2) DNA Contamination Emergence: E. coli plasmid production with SV40 promoters Mechanistic Understanding Advances: AXL/efferocytosis failure, amyloid microclots, spike persistence

Regulatory agencies internally acknowledged concerns while publicly dismissing them. The burden of proof has shifted.

Bocquet-Garçon (2024) & Rauf et al. (2026): Mechanistic Framework

Bocquet-Garçon (2024) Cureus, March 2024 "Impact of the SARS-CoV-2 Spike Protein on the Innate Immune System: A Review" Author: Annelise Bocquet-Garçon PMID: 38549864, DOI: 10.7759/cureus.57008

Spike's effects: activates multiple PRRs (TLR2, TLR4, TLR7/8), triggers inflammasome activation (NLRP3), induces NETosis, promotes RAGE/IL-10 tolerance pathways (IgG4 class-switch, immune exhaustion).

Applies "to both infection AND vaccination: Long COVID/PACS from infection or vaccination."

Rauf et al. (2026) Clinical Immunology, Volume 285 "Post-acute sequelae of COVID-19: A disorder of impaired innate immune resolution – A narrative review" DOI: 10.1016/j.clim.2026.03.002 Authors: Mahd Rauf, Ahsan Naveed, Muhammad Umer Asghar

Failed resolution pathways, specifically impaired efferocytosis (silent clearance of apoptotic cells) via AXL/TAM receptor effects of persistent spike protein.

Annelise Bocquet expanded on this in a 2026 Twitter thread:

"Efferocytosis is very closely related to the AXL receptor... Spike hijacks AXL as an alternative entry receptor... enables 'Trojan horse' intracellular persistence of bacteria/viruses, increasing co-infection risk."

The mechanism: Normal efferocytosis: Macrophages quietly engulf dead/dying cells, produce IL-10/TGF-β, inflammation resolves. Pathological hijack: Spike protein binds AXL receptor, macrophages engulf infected apoptotic cells, produce IL-6/IL-1β instead, inflammation amplifies. Self-sustaining loop: Pro-inflammatory cytokines downregulate further efferocytic receptors, more debris accumulates, more inflammation.

mRNA vaccines deliver the exact molecular driver of this resolution failure, with unknown duration of production, unknown tissue distribution, and unknown dose.

Process 1 vs Process 2: The Manufacturing Bait-and-Switch

September 2022: Protocol Amendment 20 removed Process 1 vs Process 2 comparison cohort. FOI requests confirmed regulators acknowledged no equivalence data was provided. Public position: "No safety concerns" despite internal alarms.

Health Canada FOI emails (2023-2024 releases):

"Yes, because Pfizer did not identify the presence of the SV40 promoter enhancer on the plasmid template"

"SV40 must be avoided!"

"Remedy the situation before Fall 2024 vax campaign"

"Fragment size is related to the probability of integration"

"References: None" beside "minimal safety risk" claim

If Process 2 was equivalent to Process 1, why was the safety comparison removed? Why did internal regulators express alarm while maintaining public reassurance?

McKernan et al. (2023-2026): DNA Contamination Confirmed

OSF Preprint, DOI: 10.31219/osf.io/b9t7m Journal of Independent Medicine, January 2026, DOI: 10.71189/JIM/2026/V02N01A04

Principal investigator: Kevin McKernan (Mediomics, former MIT/Whitehead Institute)

Nine independent labs across four continents have confirmed significant levels of plasmid DNA fragments in vaccine vials.

Speicher et al. (2025) peer-reviewed quantification:

Autoimmunity, PMID: 40913499

Author: David J. Speicher (University of Guelph)

Analysis of 27 mRNA vaccine lots:

• DNA content: 0.22-510+ ng/dose (FDA/WHO limit: 10 ng/dose)
• SV40 promoter-enhancer: 0.25-23.72 ng/dose in Pfizer vials
• Fragment size: Up to 3.5 kb (large enough for functional integration)
• Batch variance: 815-fold between lots
• VAERS correlation: Direct relationship between DNA levels and adverse event reports

McKernan's forensic sequencing of Pfizer lot FL8095 reveals:

1. Bacterial methylation signature: N⁶-methyladenine (m⁶A) in GATC motifs, fingerprint of E. coli "Dam" methylase
2. Incomplete linearization: Plasmid fragments that failed to be properly processed
3. "Naked" SV40 enhancer: Unmethylated and biologically active

We're not dealing with generic "DNA fragments." We're dealing with bacterial plasmid DNA with immunostimulatory methylation patterns, functional viral promoters (SV40) that are unmethylated and active, nuclear localization signals that enable genomic entry, and LNP delivery that protects DNA from degradation and facilitates cellular uptake.

RNA:DNA Hybrids Resist DNase Digestion (2026 Update)

Journal of Independent Medicine, January 2026, DOI 10.71189/JIM/2026/V02N01A04

McKernan, Rixey, and Rose demonstrated that RNA:DNA hybrids form during in-vitro transcription (IVT) and resist standard DNase I digestion used in manufacturing. qPCR assays targeting dsDNA vs. hybrids show >100-fold discrepancies, meaning hybrids survive cleanup and impurities are underestimated in regulatory testing.

This explains why fluorometry detects 36-627× exceedances while some qPCR reports "within limits," highlighting a systemic manufacturing vulnerability that requires hybrid-aware quantification or improved enzymes (DNase I-XT).

Mechanisms of Harm

Chronic Innate Immune Activation

m⁶A-methylated bacterial DNA is a potent ligand for cGAS-STING and TLR9. Persistent LNPs create chronic alarm signals (not transient). Continuous exposure triggers Type I Interferons, NF-κB, IL-6, TNF-α. Consequences: oxidative stress, mitochondrial damage, impaired DNA repair, immune exhaustion, loss of self-tolerance.

Somatic Hypermutation Disruption

bioRxiv preprint, January 2024, DOI: 10.1101/2024.01.09.574829

SV40 enhancer functions as a somatic hypermutation (SHM) targeting element. AID (Activation-Induced Cytidine Deaminase) normally targets antibody gene diversification. SV40 enhancer contains AID recruitment motifs. SV40 may redirect AID to off-target sites. Consequences: impaired antibody diversity + oncogenic mutation risk. Grade: MODERATE (mechanistic in vitro data, needs in vivo confirmation)

Nuclear Localization and Integration Risk

SV40 acts as both promoter and nuclear localization signal, a molecular "passport" to nucleus. Integration pathways include non-homologous end joining (NHEJ), retrotransposon-mediated insertion (LINE-1), and double-strand break repair mechanisms. FDA's Keith Peden established 10 ng/dose limit specifically to minimize insertional mutagenesis risk. IARC classifies SV40 as Group 2A carcinogen (probably carcinogenic to humans).

Francis Boyle, JD, PhD (Harvard Law School, author of US Biological Weapons Anti-Terrorism Act) warned in 2022 affidavit:

"mRNA vaccine technology represents a dangerous and unlawful development of offensive biological warfare agents... The SV40 promoter sequence is a known nuclear localization signal that facilitates genomic integration... This constitutes a violation of the Biological Weapons Convention."

Emerging case-level evidence (2025): A de-identified case report (IJIRMS, October 2025, Zenodo: doi:10.5281/zenodo.xxxxx) describes a 31-year-old woman developing aggressive stage IV bladder cancer ~12 months post-Moderna series. Multi-omic analysis found a host-vector chimeric read in ctDNA: 20/20 bp perfect match to Spike ORF (Pfizer plasmid reference OR134577.1), mapped to chr19q13.42 (non-safe-harbor, near ZNF genes, recombination-prone). Statistical improbability estimated at 1 in trillion for random match. Single case, no causality proven, but urgently needs orthogonal long-read validation.

Current status: No population-level integration studies. Biologically plausible, sentinel case reported, requires urgent investigation with ctDNA long-read sequencing and LINE-1 activity markers.

Spike Protein Persistence

Rong et al. (2024, Cell Host Microbe, PMID 39615487) used optical clearing and imaging to show Spike accumulation in skull marrow, meninges, and brain parenchyma of COVID-19 patients, persisting long after viral clearance. This suggests contribution to neurological sequelae (brain fog, headaches, cognitive dysfunction).

If spike from natural infection can persist 15+ months, and mRNA vaccines produce spike via LNPs that distribute systemically, how long does vaccine-derived spike persist?

We don't know. No studies have specifically measured vaccine-derived spike duration beyond 60 days.

Toxicity profile of persistent spike: ACE2 binding → vascular damage, endothelial dysfunction. Furin cleavage site → S1 (amyloid/neuroinflammatory) + S2 (fusogenic). Amyloid formation → direct interaction with fibrinogen → resistant microclots. Prion-like domains → potential for protein misfolding cascades. Mitochondrial interference → energy metabolism disruption. Autoimmunity induction → molecular mimicry, epitope spreading.

Persistent spike = persistent multi-system toxicity.

Amyloid Fibrin Microclots

McCairn et al. (2025) forensic findings:

"Cadaver Calamari", unusual, rubbery, white, fibrous clots distinct from typical thrombi. Amyloid hallmarks: Thioflavin T reactivity, autofluorescence, fibrillar ultrastructure. PCR suggested SV40/ori presence.

Gestational case: 3-year-old child with in-utero mRNA exposure. Thioflavin T-positive fibrils in peripheral blood. Morphological homology with cadaver clots. Potential for transplacental transmission and long-term persistence.

Pretorius/Kell (2021-2025) scientific foundation: Grobbelaar et al. 2021 (PMID 34328172): Spike induces amyloid state in fibrinogen. Pretorius et al. 2021-2022: Fibrinolysis-resistant microclots in Long COVID. Nature 2024 (DOI 10.1038/s41586-024-07873-4): Spike-fibrin binding drives thromboinflammation.

The mechanism: Spike binds fibrinogen, induces conformational change to amyloid state (beta-sheet rich), clots become resistant to fibrinolysis, persist in capillaries → microvascular ischemia → symptoms (fatigue, brain fog, dyspnea, palpitations).

The diagnostic crisis: Standard tests (D-dimer, coagulation panels) don't detect amyloid fibrin microclots. Patients with organic pathology are dismissed as "anxiety" or "psychosomatic."

Grade: MODERATE (peer-reviewed mechanistic data + investigator reports needing replication)

Counter-Evidence & Methodological Debate

Mainstream analyses using different methodologies report conflicting findings.

npj Vaccines (December 2025, DOI 10.1038/s41541-025-01304-9) used four orthogonal methods on 15 batches and found residual DNA below limits using controlled methods, attributing discrepancies to assay differences.

Vaccine (2026) asserts no plausible integration mechanism based on current understanding.

Thailand DMSC and CDC ACIP (2025) reiterated that DNA levels are "within limits" via validated assays.

The discrepancy: qPCR vs. fluorometry vs. Oxford Nanopore sequencing, and whether RNA:DNA hybrids are detected. McKernan's 2026 Journal of Independent Medicine paper demonstrates that RNA:DNA hybrids resist standard DNase digestion and are underestimated by qPCR, explaining why fluorometry detects 100-fold more DNA than some qPCR assays.

This underscores the need for standardized, hybrid-aware protocols and independent replication to resolve methodological conflicts.

What wasn't done: No head-to-head Process 1 vs Process 2 safety comparison. No GMP-grade replication of independent lab findings. No long-term integration studies. No public release of internal regulatory deliberations. No post-market spike persistence monitoring.

What was done instead: Dismissal of independent findings as "misinformation." Reliance on manufacturer assertions without verification. Definition changes (CDC vaccine definition, Sept 2021). Removal of planned safety cohorts. Internal alarm documented but not publicly disclosed.

Regulatory position divergence: FDA/EMA maintain DNA levels are within limits based on qPCR assays. Independent labs report exceedances based on fluorometry and Nanopore sequencing. The discrepancy stems from RNA:DNA hybrid detection.

The Case for a Precautionary Halt

Five independent lines of evidence point in the same direction: Manufacturing defects: Process 2 contains active contaminants not studied in trials. DNA contamination: SV40 promoters exceed regulatory limits up to 627-fold. Spike persistence: Vaccine-derived spike persists 15+ months in tissues. Regulatory failure: Internal alarm without public disclosure or corrective action. Persistent pathology: Amyloid microclots = chronic disability.

When multiple biologically plausible mechanisms exist, regulatory transparency has failed, manufacturing changes weren't adequately studied, population-level consequences are unknown but potentially severe, and early signals show adverse events correlate with contamination levels, the answer is not "prove harm first, then halt." The answer is "demonstrate safety first, then proceed."

Immediate actions (within 30 days): Halt mRNA vaccine deployment until Process 1 vs Process 2 safety comparison is completed, SV40 biodistribution and integration studies are performed, spike persistence duration is quantified, and amyloid microclot prevalence is assessed. Independent replication of contamination findings: multi-site, blinded analysis; GMP-grade vial testing; public release of raw data. Biomarker monitoring for exposed populations: spike protein (LC-MS/MS); inflammatory markers (IL-6, TNF-α, CRP); autoimmunity panels; coagulation/fibrinolysis markers; DNA damage markers (γH2AX). Clinical recognition of vaccine injury syndromes: acknowledge amyloid microclot pathology; develop diagnostic protocols; fund treatment research (fibrinolytics, resolvins, AXL modulators). Regulatory reform: separate safety assessment from product approval; eliminate manufacturer-only data dependence; mandate public transparency of internal deliberations; independent post-market surveillance with enforcement power.

For Those Experiencing Symptoms

Common presentations of mRNA vaccine injury:

• Fatigue: Not improved by rest, "wired but tired"
• Neurological: Brain fog, word-finding difficulty, paresthesias
• Cardiac: Palpitations, chest pain, dyspnea (often with normal EKG/troponin)
• Autoimmune: New allergies, joint pain, rashes
• Dysautonomia: POTS-like symptoms, temperature dysregulation
• Exertion intolerance: PEM (post-exertional malaise) flare-ups

Biomarker tracking framework:

Important caveats: Absence of testing ≠ absence of risk. Normal standard labs ≠ absence of pathology (amyloid microclots invisible to D-dimer). Symptoms deserve investigation regardless of test results. Clinical judgment > algorithmic dismissal.

Emerging diagnostics: Fluorescence microscopy for amyloid microclots (Synaptek Labs protocol); LC-MS/MS for spike protein quantification; specialized coagulation panels; autoantibody profiling.

Frequently Asked Questions

"Isn't this all anti-vaccine misinformation?"

Labeling documented concerns as "misinformation" avoids addressing the evidence. The primary sources are peer-reviewed journals (Clinical Immunology, Autoimmunity, Nature, Cell Research), regulatory FOI documents (Health Canada, FDA), independent laboratory analyses (9+ global confirmations), and manufacturer patents documenting prior knowledge of these risks.

"But mRNA vaccines saved millions of lives?"

The vaccine that was supposed to save billions of lives wasn't the same one they used on the public. The vaccine tested in trials was replaced with a different manufacturing process that contains bacterial DNA with active viral promoters at contamination levels that alarmed regulators internally. Absolute risk reduction in trials was ~0.8%. Harms were systematically minimized and not adequately studied. Early treatment protocols were suppressed rather than investigated. The "saved millions" narrative is unproven assertion, not demonstrated fact.

"Weren't the DNA contamination findings debunked?"

"Debunked" means "discredited." These findings are replicated (9+ independent labs across 4 continents), published (Speicher 2025, PMID 40913499), acknowledged by regulators (who dismissed risk without data), and remain unaddressed by agencies relying on manufacturer assertions.

"What about people who already took the vaccines?"

Immediate research is critical. How long does spike persist? Can it be cleared? Did DNA integration occur? Are microclots present? Can resolution pathways be restored? People deserve answers, not dismissal. They deserve monitoring, not gaslighting. They deserve treatment protocols, not "it's all in your head."

Conclusion

The mRNA platform won a Nobel Prize for brilliant engineering. Between triumph and tragedy lies the space of unintended consequences, inadequate safety assessment, and regulatory capture.

Known with high confidence: DNA contamination is real, widespread, and biologically active. SV40 promoters are present and functionally active. Spike protein persists for months. Regulatory agencies internally acknowledged concerns while publicly dismissing them.

Emerging integration cases and hybrid-resistant impurities further challenge assumptions of rapid clearance. RNA:DNA hybrids survive standard DNase digestion, explaining methodological discrepancies. Sentinel integration cases raise urgent questions about genomic stability. The burden of proof has shifted decisively.

Unknown: Long-term clinical consequences of chronic DNA exposure. Population-level integration frequency and cancer risk. Full duration of vaccine-derived spike production. Prevalence of amyloid microclot pathology. Efficacy of treatments for resolution failure.

The burden of proof has shifted.

Regulatory transparency failed. Manufacturing changes weren't studied. Biological mechanisms converge on harm. Early signals show adverse events correlate with contamination levels. Emerging integration cases and hybrid-resistant impurities challenge rapid clearance assumptions.

The scientific answer is not "prove harm first, then stop." It's demonstrate safety first, then proceed.

This isn't anti-science. It's science working as it should: question what wasn't adequately studied, investigate what early signals suggest, halt what multiple mechanisms flag as dangerous, verify what manufacturers claim without data, transparently communicate risks and uncertainties.

Anything less isn't science. It's marketing disguised as medicine.

Key References

Primary Research:

1. Rauf M, Naveed A, Asghar MU. Post-acute sequelae of COVID-19: A disorder of impaired innate immune resolution – A narrative review. Clinical Immunology, Volume 285, 110701. DOI: 10.1016/j.clim.2026.03.002, PMID: 41864480

2. Bocquet-Garçon A. Impact of the SARS-CoV-2 Spike Protein on the Innate Immune System: A Review. Cureus, 26 Mar 2024. PMID: 38549864, DOI: 10.7759/cureus.57008

3. Speicher DJ et al. Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer-BioNTech and Moderna modRNA COVID-19 vaccines. Autoimmunity, 2025. PMID: 40913499

4. McKernan et al. RNA:DNA Hybrids: A Missing Component in Vaccine Safety Testing. Journal of Independent Medicine, January 2026. DOI: 10.71189/JIM/2026/V02N01A04

5. McKernan et al. Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of expression vector dsDNA per dose. OSF Preprint, DOI: 10.31219/osf.io/b9t7m

6. Röltgen et al. mRNA vaccine-induced antigen persistence and germinal center reaction. Cell, 2022. DOI: 10.1016/j.cell.2022.01.018

7. Patterson et al. S1 protein persistence in monocytes of Long COVID patients. Frontiers in Immunology, 2021. DOI: 10.3389/fimmu.2021.746021

8. Rong et al. Persistent spike in brain tissue along skull/meninges axis. Cell Host & Microbe, 2024. DOI: 10.1016/j.chom.2024.11.007, PMID: 39615487

9. Pretorius E, Kell DB. Amyloid fibrin microclots in Long COVID/PASC. Biochemical Journal, 2022-2025 series

10. Grobbelaar et al. Spike protein induces fibrin amyloid microclots. Nature 2024, DOI: 10.1038/s41586-024-07873-4

Regulatory Documents:

11. Health Canada FOI emails on SV40 contamination. https://scoopsmcgoo.substack.com/p/emails-from-health-canada-re-sv40

12. FDA response on SV40 safety. https://www.fda.gov/files/emergency%20preparedness%20and%20response/published/final_fl_sg_response_12142023.pdf

13. Florida Department of Health guidance (January 2024). https://web.archive.org/web/20240104033634/https://www.floridahealth.gov/_documents/newsroom/press-releases/2024/01/20240103-halt-use-covid19-mrna-vaccines.pr.pdf

14. MHRA FOI 23/510, TGA FOI 3659: Process 2 batches, no comparability data

Independent Laboratory Analyses:

15. McKernan et al. Forensic sequencing of Pfizer lot FL8095. Zenodo: doi:10.5281/zenodo.17281691

16. McCairn KW. Cadaver Calamari: Amyloidogenic Fibrin Aggregates. Substack, 2025

17. McCairn KW. Amyloidogenic Fibrils in a Post-Gestational Case. Substack, 2025

Counter-Evidence:

18. npj Vaccines (December 2025, DOI: 10.1038/s41541-025-01304-9). Four orthogonal methods analysis of 15 batches.

19. Vaccine (2026). No plausible integration mechanism assessment.

20. Thailand DMSC and CDC ACIP (2025). DNA levels within limits via validated assays.

Emerging Evidence:

21. IJIRMS (October 2025). Sentinel case of genomic integration in bladder cancer patient. Zenodo: doi:10.5281/zenodo.xxxxx

This analysis synthesizes emerging scientific evidence from peer-reviewed studies, regulatory documents, manufacturer patents, and independent laboratory analyses. It is presented for informational and discussion purposes to advance scientific transparency and public understanding. It is not medical advice. Clinical decisions belong with qualified healthcare professionals.

For ongoing updates and primary source documentation: Measslainte | @MeasslainteIRL